What are the FDA‑approved infusion therapies for dementia (Alzheimer’s disease)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

FDA-Approved Infusion Therapies for Alzheimer's Disease

The "dementia infusion treatment" refers to FDA-approved anti-amyloid monoclonal antibodies administered intravenously for early-stage Alzheimer's disease: lecanemab (Leqembi) and donanemab (Kisunla) are the currently available disease-modifying infusion therapies, while aducanumab (Aduhelm) has been discontinued. 1

Currently Available Infusion Therapies

Lecanemab (Leqembi)

  • FDA Status: Full traditional approval (July 2023) with CMS reimbursement when patients are registered in approved registries 1
  • Administration: Intravenous infusion every 2 weeks 2
  • Indication: Early-stage Alzheimer's disease (mild cognitive impairment or mild dementia) with confirmed brain amyloid pathology 3
  • Mechanism: Targets and removes amyloid-beta plaques from the brain 4
  • Clinical Benefit: 27% reduction in clinical worsening on CDR-SB scale (mean difference -0.45) over 18 months, representing modest but statistically significant slowing of cognitive decline 5

Donanemab (Kisunla)

  • FDA Status: Traditional approval recommended unanimously by FDA advisory panel (June 2024) 1
  • Administration: Intravenous infusion once every 4 weeks 2
  • Indication: Early symptomatic Alzheimer's disease with confirmed amyloid pathology 6
  • Mechanism: Targets pyroglutamate-modified amyloid-beta aggregates 6

Aducanumab (Aduhelm) - Discontinued

  • FDA Status: Accelerated approval granted (June 2021), but development and sale discontinued 1
  • Historical Note: CMS did not support payment, severely limiting its use before discontinuation 1

Critical Safety Considerations

Amyloid-Related Imaging Abnormalities (ARIA)

Both lecanemab and donanemab carry significant risk of ARIA, which includes:

  • ARIA-E (edema): Vasogenic brain edema
  • ARIA-H (hemorrhage): Cerebral microhemorrhages and rare macrohemorrhages 7
  • Incidence: Approximately 21.5% with lecanemab versus 9% with placebo 5
  • Risk Factors: APOE4 gene carriers, especially homozygotes, face substantially higher ARIA risk 3

Absolute Contraindications

Patients requiring anticoagulation should NOT receive these therapies until more safety data are available, as anticoagulation significantly increases hemorrhage risk 3

Required Pre-Treatment Workup

Before initiating infusion therapy, patients must have:

  1. Confirmed amyloid pathology via:

    • Amyloid PET scan (now Medicare-reimbursable as of October 2023) 1, OR
    • CSF biomarkers for amyloid and tau 1
  2. APOE genotyping to assess ARIA risk and inform patient discussions 3, 8

  3. Baseline brain MRI to monitor for ARIA during treatment 1

  4. Cognitive staging confirming mild cognitive impairment or mild dementia (not moderate-to-severe dementia) 3

Monitoring Requirements

  • Serial MRI scans throughout treatment to detect ARIA 7
  • Clinical assessment for infusion reactions and neurological symptoms
  • Institutional preparedness with protocols for managing serious adverse events 3

Comparison to Traditional Dementia Medications

These infusion therapies differ fundamentally from oral medications:

Traditional oral medications (donepezil, rivastigmine, galantamine, memantine):

  • Provide only symptomatic relief 4
  • Do NOT modify disease progression 4
  • Administered orally, typically daily 9, 10

Infusion therapies (lecanemab, donanemab):

  • Target underlying disease pathology (amyloid plaques) 4
  • Provide disease-modifying effects with modest slowing of decline 5
  • Require IV administration every 2-4 weeks 7, 2
  • Carry significant monitoring burden and ARIA risks 7, 3

Patient Selection Algorithm

Appropriate candidates:

  • Early-stage AD (MCI or mild dementia only)
  • Confirmed amyloid pathology
  • No anticoagulation requirement
  • Able to undergo regular MRI monitoring
  • Understanding of modest benefits versus significant risks
  • Access to specialized infusion centers with multidisciplinary teams 1

Inappropriate candidates:

  • Moderate-to-severe dementia 3
  • Cognitively unimpaired individuals 1
  • Patients requiring anticoagulation 3
  • Inability to comply with monitoring requirements
  • Dementia suspected due to Lewy body disease 1

Clinical Reality

The clinical benefit of these infusion therapies is modest - the observed improvement falls short of what is typically considered the minimal clinically significant difference for this population 5. However, they represent the first treatments that actually modify disease progression rather than merely treating symptoms 4. The decision to use these therapies requires careful weighing of modest cognitive benefits against substantial monitoring burden, infusion requirements, ARIA risks, and costs 8.

References

Research

Lecanemab: Appropriate Use Recommendations.

The journal of prevention of Alzheimer's disease, 2023

Related Questions

What is the optimal management for a 72‑year‑old patient with dementia who is refusing hygiene and medication, becoming agitated and aggressive toward staff, has low motivation and frequent incontinence, and is currently on donepezil 10 mg daily, memantine 10 mg daily, sertraline 150 mg daily, mirtazapine 15 mg daily (dose recently increased), olanzapine 2.5 mg daily, after discontinuation of valproic acid (Depakote) 125 mg twice daily one month ago?
In an 84-year-old patient with sciatic pain, hypertension, and Alzheimer's disease, is meloxicam safe to use as needed?
How should visual hallucinations in an elderly patient with Alzheimer’s disease be managed?
What are the recommended pharmacologic and non‑pharmacologic treatments for Alzheimer's disease, including dosing and management of side effects?
What is the optimal management, including medication adjustments and non‑pharmacologic strategies, for a 50‑year‑old woman with vascular dementia who is very combative and anxious while taking brexpiprazole (Rexulti) 2 mg at bedtime, a rivastigmine transdermal patch, and olanzapine (Zyprexa) 5 mg twice daily?
How is a gentle eyelid massage performed?
What is the earliest age at which the MenQuadfi (quadrivalent MenACWY) vaccine can be administered?
What is the recommended protocol for tapering clonidine and initiating prazosin (alpha‑1 blocker) dosing, including titration schedule and monitoring?
In a 30-year-old Black male (6'5", 320 lb) with hypertension on amlodipine and GLP‑1 therapy, who has a positive ANA (1:160 speckled), markedly elevated anti‑U1‑RNP, negative anti‑centromere, anti‑Scl‑70, anti‑Sm, anti‑SSA/SSB, and anti‑dsDNA, normal complement C3/C4, mildly elevated CK (371–527 U/L), low‑normal ESR (2–18 mm/h), normal renal and liver function, and an upcoming EMG, what is the most likely diagnosis (inflammatory myositis associated with mixed connective‑tissue disease versus necrotizing autoimmune myopathy), is a muscle biopsy required, and how serious is the condition?
Do patients with atrial flutter who have undergone left atrial appendage (LAA) ligation need to continue anticoagulation?
What is the onset of clinical efficacy and time to full therapeutic effect of oxcarbazepine?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.